-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the intensification of aging, the increase in the incidence of chronic disease patients, and the continuous upgrading of consumption, people are paying more attention to health, and the future development of the pharmaceutical and health industry is huge
.
According to Zhongkang CMH's forecast, the average growth rate of the health industry will reach 9.
5% in the first five years of the "14th Five-Year Plan", and the average growth rate in the next five years will drop to about 6.
5%, and the scale of the industry will reach 16.
3 trillion
.
So, what are the contents worth paying attention to in the future development of the pharmaceutical and health industry? From the perspective of the industry, the pharmaceutical e-commerce market may become the outlet for the development of the pharmaceutical and health industry in the future
.
The medical e-commerce market or the popular medical e-commerce refers to the market economy entities with the purpose of profit, such as medical institutions, pharmaceutical companies, banks, pharmaceutical manufacturers, medical information service providers, and third-party institutions, relying on computer and network technology ( Mainly the Internet) and other modern information technologies, the exchange of medical products and the provision of related services
.
According to data from the China Business Industry Research Institute, the size of China's pharmaceutical e-commerce market has increased from 95 billion yuan in 2016 to 199.
5 billion yuan in 2020, with an average annual compound growth rate of 19.
8%
.
The China Business Industry Research Institute predicts that China's pharmaceutical e-commerce market will reach 209.
33 billion yuan in 2021
.
In addition, from the perspective of the marketing model, the main marketing scale of China's pharmaceutical e-commerce is the B2B model, which is a marketing model for the exchange of products, services and information between enterprises and enterprises through the Internet
.
Through the B2B platform, enterprises can directly face small and medium-sized distributors, chain backbone single pharmacies, clinics, etc.
, that is, modern pharmaceutical distribution, and complete the information connection between medical institutions and pharmaceutical companies
.
The data shows that the pharmaceutical e-commerce market under the B2B model has grown rapidly, from 107.
58 billion yuan in 2016 to 204.
71 billion yuan in 2019
.
The China Business Industry Research Institute predicts that in 2021, the pharmaceutical e-commerce market under the B2B model in my country will reach 258.
57 billion yuan, and the market under the B2C model will reach 140.
02 billion yuan.
.
Opportunities and challenges coexist It is understood that prescription drugs account for 80% of the entire domestic drug market.
In recent years, the industry has paid great attention to the implementation of prescription drug liberalization policies.
This policy will also have a certain impact on the pharmaceutical e-commerce industry
.
Not long ago, it was reported in the industry that the State Food and Drug Administration recently solicited opinions on the "Measures for the Supervision and Administration of Drug Online Sales" (Draft for Review) (hereinafter referred to as the "Administrative Measures"), covering drug online sales management, platform management, and supervision.
Management, legal liability, etc.
, the policy is expected to be implemented on December 1, 2021
.
In this regard, many people in the industry believe that the policy is conducive to promoting the opening of online prescription drugs
.
Once the policy on online sales of prescription drugs is liberalized, it means that the pharmaceutical e-commerce market will soar again, and it will also attract more companies to accelerate market layout
.
Statistics show that in the past five years, the number of electronic prescription-related companies in China has continued to grow rapidly.
In 2019, more than 2,500 related companies were added, with a growth rate of 53.
96%, a record high
.
It is worth mentioning that with the promulgation of the "Administrative Measures", the supervision of online prescription drugs will become more stringent, including the need for online platforms to strictly implement "prescription before medicine" and the need for prescription drug information display, which may trigger The rejection of users and the loss of some users.
Therefore, this policy may be a challenge for online medical e-commerce platforms, especially for platforms with a large share of B2C business.
In the future, the entire medical e-commerce platform will usher in a wave of reshuffle
.
.
According to Zhongkang CMH's forecast, the average growth rate of the health industry will reach 9.
5% in the first five years of the "14th Five-Year Plan", and the average growth rate in the next five years will drop to about 6.
5%, and the scale of the industry will reach 16.
3 trillion
.
So, what are the contents worth paying attention to in the future development of the pharmaceutical and health industry? From the perspective of the industry, the pharmaceutical e-commerce market may become the outlet for the development of the pharmaceutical and health industry in the future
.
The medical e-commerce market or the popular medical e-commerce refers to the market economy entities with the purpose of profit, such as medical institutions, pharmaceutical companies, banks, pharmaceutical manufacturers, medical information service providers, and third-party institutions, relying on computer and network technology ( Mainly the Internet) and other modern information technologies, the exchange of medical products and the provision of related services
.
According to data from the China Business Industry Research Institute, the size of China's pharmaceutical e-commerce market has increased from 95 billion yuan in 2016 to 199.
5 billion yuan in 2020, with an average annual compound growth rate of 19.
8%
.
The China Business Industry Research Institute predicts that China's pharmaceutical e-commerce market will reach 209.
33 billion yuan in 2021
.
In addition, from the perspective of the marketing model, the main marketing scale of China's pharmaceutical e-commerce is the B2B model, which is a marketing model for the exchange of products, services and information between enterprises and enterprises through the Internet
.
Through the B2B platform, enterprises can directly face small and medium-sized distributors, chain backbone single pharmacies, clinics, etc.
, that is, modern pharmaceutical distribution, and complete the information connection between medical institutions and pharmaceutical companies
.
The data shows that the pharmaceutical e-commerce market under the B2B model has grown rapidly, from 107.
58 billion yuan in 2016 to 204.
71 billion yuan in 2019
.
The China Business Industry Research Institute predicts that in 2021, the pharmaceutical e-commerce market under the B2B model in my country will reach 258.
57 billion yuan, and the market under the B2C model will reach 140.
02 billion yuan.
.
Opportunities and challenges coexist It is understood that prescription drugs account for 80% of the entire domestic drug market.
In recent years, the industry has paid great attention to the implementation of prescription drug liberalization policies.
This policy will also have a certain impact on the pharmaceutical e-commerce industry
.
Not long ago, it was reported in the industry that the State Food and Drug Administration recently solicited opinions on the "Measures for the Supervision and Administration of Drug Online Sales" (Draft for Review) (hereinafter referred to as the "Administrative Measures"), covering drug online sales management, platform management, and supervision.
Management, legal liability, etc.
, the policy is expected to be implemented on December 1, 2021
.
In this regard, many people in the industry believe that the policy is conducive to promoting the opening of online prescription drugs
.
Once the policy on online sales of prescription drugs is liberalized, it means that the pharmaceutical e-commerce market will soar again, and it will also attract more companies to accelerate market layout
.
Statistics show that in the past five years, the number of electronic prescription-related companies in China has continued to grow rapidly.
In 2019, more than 2,500 related companies were added, with a growth rate of 53.
96%, a record high
.
It is worth mentioning that with the promulgation of the "Administrative Measures", the supervision of online prescription drugs will become more stringent, including the need for online platforms to strictly implement "prescription before medicine" and the need for prescription drug information display, which may trigger The rejection of users and the loss of some users.
Therefore, this policy may be a challenge for online medical e-commerce platforms, especially for platforms with a large share of B2C business.
In the future, the entire medical e-commerce platform will usher in a wave of reshuffle
.
